NOXXON Pharma AG Announces Appointment of Lawrence E. Posner to Its Board of Directors

July 8, 2008 |

1 min read

BERLIN--(BUSINESS WIRE)--NOXXON Pharma AG (NOXXON), developer of mirror image oligonucleotide therapeutics termed Spiegelmers®, announced today the appointment of Lawrence E. Posner, MD, to its Board of Directors.

People Europe

MORE ON THIS TOPIC

Conceptual origami paper plane pulling business finance growth chart line flying upwards on blue sky background.

Rare diseases

Rare Disease Sales To Soar to $400B+ By 2032 as Small Molecules Resurgent: Evaluate

March 13, 2026

·

2 min read

·

Tristan Manalac

Jamaica economic collapse, decreasing values with coins, crisis and downgrade concept, Jamaica flag with changes, falling arrow, news banner idea, fail and decrease, financial decline

Earnings

Novo Holdings’ Assets Fell 34% in 2025 As Its Namesake Drugmaker Struggled

March 12, 2026

·

1 min read

·

Annalee Armstrong

Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant

Layoff Tracker

Vistagen, Evotec, Reckitt Benckiser Downsize, Collectively Affecting Hundreds

March 12, 2026

·

35 min read

·

BioSpace Editorial Staff

Magnifier magnifying exclamation mark on red background. Alert and precaution concept. Caution and risk management security signal announcement hazard and dangerous notice symbol

Weight loss

Lilly Flags ‘Concerning’ Impurities in Compounded Tirzepatide

March 12, 2026

·

2 min read

·

Tristan Manalac